E. coli Autovaccine for House Dust Mite Asthma
Author Information
Author(s): Rose Markus, Weigand Bianca, Schubert Ralf, Schulze Johannes, Zielen Stefan
Primary Institution: Children's and Adolescents' Hospital, Goethe University
Hypothesis
Can autologous E. coli autovaccine reduce allergic inflammation in house dust mite asthma?
Conclusion
The autologous autovaccine treatment led to a reduction in exhaled nitric oxide levels, indicating decreased allergic inflammation.
Supporting Evidence
- 101 episodes of local erythema were observed, indicating mild local reactions.
- Median eNO levels increased significantly less after treatment compared to before.
- No serious adverse events were reported during the study.
Takeaway
This study tested a vaccine made from a person's own E. coli to see if it helps with asthma caused by dust mites, and it showed some positive results.
Methodology
A prospective open trial with 9 subjects receiving 306 injections of an autologous E. coli autovaccine, measuring exhaled nitric oxide before and after treatment.
Potential Biases
Self-reported symptoms may introduce bias.
Limitations
Small sample size and potential type 2 errors due to limited applications.
Participant Demographics
9 subjects (6 females, 3 males), aged 18-50, with mild persistent house dust mite asthma.
Statistical Information
P-Value
0.034
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website